Skip to main content
Clinical Trials/NL-OMON54336
NL-OMON54336
Not yet recruiting
Phase 2

Treatment study for children and adolescents with Acute Promyelocytic Leukemia - ICC APL Study 02

AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica0 sites5 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica
Enrollment
5
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica

Eligibility Criteria

Inclusion Criteria

  • \- Newly diagnosed APL confirmed by the presence of PML/RARa fusion gene
  • \- Age \<18 years
  • \- Written informed consent by parents or legal guardians
  • \- If applicable, female participants must have pregnancy test by beta\-HCG
  • dosing and be negative.
  • \- Patients of child\-bearing or child\-fathering potential must be willing to
  • practice the most appropriate approach for birth control from the time of
  • enrollment in this study and for 3 months after receiving the latest infusion.

Exclusion Criteria

  • \- Patients with a clinical diagnosis of APL but subsequently found to lack
  • PML/RARa rearrangement should be withdrawn from the study and treated with an
  • alternative protocol
  • \- Significant liver dysfunction (bilirubin serum levels \>3 mg/dL, ALT/AST serum
  • levels \>5x the normal values)
  • \- Creatinine serum levels \>2 times the normal value for age
  • \- Significant arrhythmias, ECG abnormalities, other cardiac contraindications
  • (L\-FEV \<\= 50% or LV\-FS \<\=28%)
  • \- Neuropathy grade 2 or greater
  • \- Concurrent active malignancy

Outcomes

Primary Outcomes

Not specified

Similar Trials